Company Profile
Genflow Biosciences provides the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion.
The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin. Its portfolio also includes GF-1004, a non-human pipeline anti-aging for veterinary use, GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia, and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma.
The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. It also has a strategic technology collaboration with Acuitas Therapeutics. Founded in 2020, Genflow Biosciences is headquartered in London, the United Kingdom.